Skip to main content

Table 2 Incidence of neuropathic symptoms within 24 weeks after cART initiation

From: Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study

Interval (weeks) Incident SN r1 R1
0 – 2 6 0.06 0.06
2 – 4 10 0.10 0.15
4 – 12 16 0.14 0.27
12 – 24 4 0.04 0.30
  1. r1 is calculated as the ratio of the number of individuals who developed neuropathic symptoms to the number of patients at risk during the interval.
  2. R1 is the cumulative rate of development of neuropathic symptoms by end of the interval.
  3. For further analysis, 2 individuals with incident neuropathic symptoms were excluded due to detectable HIV-1 viral loads at week 24.